机器人立体定向体部放疗补救治疗放疗后局部前列腺癌复发:Oscar Lambret中心初步结果
该回顾性研究纳入23例放疗后前列腺内局部复发患者,采用机器人SBRT 36 Gy/6次隔日照射。中位随访22个月,82.6%患者PSA下降,2年无病生存率和总生存率分别为54%和100%,未观察到4-5级毒性。结论认为SBRT补救治疗可行且耐受良好,但需前瞻性评估。
要点
- 放疗后前列腺局部复发患者接受机器人SBRT 36 Gy/6次,PSA下降率82.6%,2年无病生存率54%。
- 中位随访22个月,9例(39.1%)出现疾病进展,其中局部5例、转移3例、淋巴结1例。
- 未观察到4-5级毒性,3级毒性2例(膀胱炎2例、神经痛1例)。
核心结论
- SBRT用于放疗后局部前列腺癌复发补救治疗短期随访显示可行且耐受良好,但需前瞻性评估。
研究设计与样本
- 回顾性研究,纳入2011年8月至2014年2月在本中心接受SBRT补救治疗的23例放疗后前列腺内复发患者,中位随访22个月(范围6-40个月)。
- SBRT处方剂量36 Gy分6次,隔日照射;20例经活检证实复发;初始治疗为EBRT者19例、近距离治疗者4例。
主要发现
- SBRT后82.6%患者PSA下降,中位PSA最低值0.35 ng/ml,中位达最低值时间8个月(范围1-30个月)。
- 2年无病生存率和总生存率分别为54%和100%。
- 9例(39.1%)出现疾病进展:局部5例、转移3例、淋巴结1例,中位进展时间20个月(范围7-40个月)。
- 未观察到4级或5级毒性;2例出现3级毒性(膀胱炎2例、神经痛1例);其他毒性包括泌尿系毒性(2级5例、1级9例)和直肠毒性(2级2例、1级2例)。
关键数值与推荐
- SBRT处方剂量为36 Gy分6次,隔日照射。
- 复发时10例存在包膜外侵犯;14例接受雄激素剥夺治疗,中位在SBRT后1个月(范围0-24个月)可停止。
- 从初始治疗到复发的中位时间为65个月(范围28-150个月)。
临床怎么用
- 对于放疗后活检证实的局限性前列腺内复发,可考虑机器人SBRT 36 Gy/6次作为补救治疗选项,需经多学科评估。
- 治疗前应评估包膜外侵犯情况,治疗后需监测PSA和泌尿、直肠毒性。
局限性
- 回顾性研究,样本量小(23例),随访时间短(中位22个月)。
- 部分患者复发未全部经活检证实(20/23例活检证实)。
- 雄激素剥夺治疗的使用和停止时间不统一,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, there is no standard option for local salvage treatment for local prostate cancer recurrence after radiotherapy. Our objective was to investigate the feasibility and efficiency of Robotic Stereotactic Body Radiation Therapy (SBRT) in this clinical setting. METHODS/MATERIALS: We retrospectively reviewed patients who were treated at our institution with SBRT for local prostate cancer recurrence after External Beam Radiation Therapy (EBRT) or brachytherapy. Multidisciplinary staff approved the treatment, and recurrence was biopsy-proven when feasible. A dose of 36 Gy was prescribed in six fractions. Treatment was delivered every other day. RESULTS: Between August 2011 and February 2014, 23 patients were treated with SBRT for intra-prostate cancer recurrence with a median follow up of 22 months (6 to 40). Twenty patients had biopsy-proven recurrence. For 19 patients, EBRT was the initial treatment and in four patients, brachytherapy was the initial treatment; the median relapse-time from initial treatment was 65 months (28 to 150). At relapse, 10 patients had an extra-capsular extension. Fourteen patients were treated with androgen deprivation that could be stopped after a median of 1 month after SBRT (range 0-24). A PSA decrease occurred in 82.6% of the patients after SBRT. The 2-year disease-free survival and overall survival rates were 54 and 100%, respectively. Disease progression was observed for nine patients (39.1%) (five local, three metastatic and one nodal progression) after a median of 20 months (7-40 months). The median nadir PSA was 0.35 ng/ml and was achieved after a median of 8 months (1 to 30) after treatment. We observed no grade 4 or 5 toxicity. Two patients presented with grade 3 toxicities (two Cystitis and one neuralgia). Other toxicities included urinary toxicities (five grade 2 and nine grade 1) and rectal toxicities (two grade 2 and two grade 1). CONCLUSION: SBRT for local prostate cancer recurrence seems feasible and well tolerated with a short follow up. Prospective evaluation is needed.
引用
- Leroy T, Lacornerie T, Bogart E, et al. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center. Radiat Oncol. 2017. PMID: 28599663. doi:10.1186/s13014-017-0833-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。